{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:49:12Z","timestamp":1786117752987,"version":"build-2736575974"},"reference-count":81,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007595","name":"Belarusian Republican Foundation for Fundamental Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017638","name":"Ministry of Health of the Russian Federation","doi-asserted-by":"publisher","award":["NUYO-2026-0024 1025022500135-4-3.2.21"],"award-info":[{"award-number":["NUYO-2026-0024 1025022500135-4-3.2.21"]}],"id":[{"id":"10.13039\/501100017638","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Steroids"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.steroids.2026.109807","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T23:55:43Z","timestamp":1780012543000},"page":"109807","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Synthesis and cytotoxicity evaluation of steroidal 17\u03b2-hydroxy-17\u03b1-methylisoxazoles"],"prefix":"10.1016","volume":"233-234","author":[{"given":"Anastasia","family":"Krech","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Aleksandrova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arif","family":"Mekhtiev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Timoshenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Kugaevskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Zavialova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirill","family":"Scherbakov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Chernysheva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danila","family":"Sorokin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Scherbakov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsiana","family":"Tsybruk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Grabovec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Zhabinskii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Khripach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.steroids.2026.109807_b0005","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1186\/s12957-025-03937-5","article-title":"Global, regional, and national burden and trends of prostate cancer in elderly from 1990 to 2021: results from global burden of disease 2021","volume":"23","author":"Li","year":"2025","journal-title":"World J. Surg. Oncol."},{"key":"10.1016\/j.steroids.2026.109807_b0010","doi-asserted-by":"crossref","unstructured":"P. Rawla, Epidemiology of Prostate Cancer, World journal of oncology 10(2) (2019) 63-89. 10.14740\/wjon1191.","DOI":"10.14740\/wjon1191"},{"issue":"1","key":"10.1016\/j.steroids.2026.109807_b0015","first-page":"3","article-title":"Androgen Receptor Structure, Function and Biology: from Bench to Bedside","volume":"37","author":"Davey","year":"2016","journal-title":"The Clinical Biochemist. Reviews"},{"key":"10.1016\/j.steroids.2026.109807_b0020","article-title":"Testosterone and cancers: biological functions, molecular mechanisms and therapy","author":"Zhou","year":"2026","journal-title":"Mol. Cancer"},{"issue":"12","key":"10.1016\/j.steroids.2026.109807_b0025","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1093\/jnci\/91.12.1017","article-title":"Cancer surveillance series: interpreting trends in prostate cancer\u2013part I: evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates","volume":"91","author":"Hankey","year":"1999","journal-title":"J. Natl Cancer Inst."},{"issue":"1","key":"10.1016\/j.steroids.2026.109807_b0030","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41392-022-01042-7","article-title":"Targeting signaling pathways in prostate cancer: mechanisms and clinical trials","volume":"7","author":"He","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"issue":"6","key":"10.1016\/j.steroids.2026.109807_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2025.104384","article-title":"A review of the efficacy of prostate cancer therapies against castration-resistant prostate cancer","volume":"30","author":"Zhang","year":"2025","journal-title":"Drug Discov. Today"},{"issue":"10","key":"10.1016\/j.steroids.2026.109807_b0040","article-title":"Advances in Prostate Cancer Treatment: Exploring Molecular Targets and New strategies in Castration-Resistant Disease","volume":"17","author":"Gopi","year":"2025","journal-title":"Cureus"},{"issue":"5","key":"10.1016\/j.steroids.2026.109807_b0045","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2165\/00002512-199812050-00006","article-title":"Bicalutamide in advanced prostate cancer","volume":"12","author":"Goa","year":"1998","journal-title":"A Review, Drugs & Aging"},{"issue":"2","key":"10.1016\/j.steroids.2026.109807_b0050","first-page":"104","article-title":"Flutamide","volume":"1","author":"Brogden","year":"1991","journal-title":"A Review of Its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Use in Advanced Prostatic Cancer, Drugs & Aging"},{"issue":"1\u20132","key":"10.1016\/j.steroids.2026.109807_b0055","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jsbmb.2010.11.005","article-title":"CYP17 inhibitors for prostate cancer therapy","volume":"125","author":"Vasaitis","year":"2011","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"1","key":"10.1016\/j.steroids.2026.109807_b0060","first-page":"149","article-title":"Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome","volume":"63","author":"Hara","year":"2003","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.steroids.2026.109807_b0065","first-page":"1395","article-title":"The antiandrogen bicalutamide activates the androgen receptor (AR) with a mutation in codon 741 through the mitogen activated protein kinase (MARK) pathway in human prostate cancer PC3 cells","volume":"24","author":"Terakawa","year":"2010","journal-title":"Oncol. Rep."},{"issue":"1","key":"10.1016\/j.steroids.2026.109807_b0070","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/aps.2014.18","article-title":"Androgen receptor: structure, role in prostate cancer and drug discovery","volume":"36","author":"Tan","year":"2015","journal-title":"Acta Pharmacol. Sin."},{"issue":"3","key":"10.1016\/j.steroids.2026.109807_b0075","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/prot.22592","article-title":"Study of the impact of the T877A mutation on ligand-induced helix-12 positioning of the androgen receptor resulted in design and synthesis of novel antiandrogens","volume":"78","author":"Zhou","year":"2010","journal-title":"Proteins"},{"key":"10.1016\/j.steroids.2026.109807_b0080","doi-asserted-by":"crossref","unstructured":"M.D. Balbas, M.J. Evans, D.J. Hosfield, J. Wongvipat, V.K. Arora, P.A. Watson, Y. Chen, G.L. Greene, Y. Shen, C.L. Sawyers, Overcoming mutation-based resistance to antiandrogens with rational drug design, eLife 2 (2013) e00499. 10.7554\/eLife.00499.","DOI":"10.7554\/eLife.00499"},{"issue":"4","key":"10.1016\/j.steroids.2026.109807_b0085","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/1758834016642370","article-title":"CYP17 inhibitors in prostate cancer: latest evidence and clinical potential","volume":"8","author":"Alex","year":"2016","journal-title":"Therapeutic Advances in Medical Oncology"},{"issue":"1","key":"10.1016\/j.steroids.2026.109807_b0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev-med-121211-091605","article-title":"Abiraterone and novel antiandrogens: overcoming castration resistance in prostate cancer","volume":"64","author":"Ferraldeschi","year":"2013","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.steroids.2026.109807_b0095","doi-asserted-by":"crossref","unstructured":"A.S. Latysheva, V.A. Zolottsev, V.S. Pokrovsky, Khan, II, A.Y. Misharin, Novel nitrogen containing steroid derivatives for prostate cancer treatment, Current medicinal chemistry 28(40) (2021) 8416-8432. 10.2174\/0929867328666210208113919.","DOI":"10.2174\/0929867328666210208113919"},{"issue":"1","key":"10.1016\/j.steroids.2026.109807_b0100","doi-asserted-by":"crossref","first-page":"23","DOI":"10.22159\/ijap.2025v17i1.51915","article-title":"Exploring potential of novel heterocyclic compounds and their structure-activity relationship in prostate cancer treatment","volume":"17","author":"Nayak","year":"2025","journal-title":"International Journal of Applied Pharmaceutics"},{"issue":"1","key":"10.1016\/j.steroids.2026.109807_b0105","doi-asserted-by":"crossref","DOI":"10.1080\/14756366.2025.2483818","article-title":"Discovery and development of steroidal enzyme inhibitors as anti-cancer drugs: state-of-the-art and future perspectives","volume":"40","author":"Cerra","year":"2025","journal-title":"J. Enzyme Inhib. Med. Chem."},{"issue":"11","key":"10.1016\/j.steroids.2026.109807_b0110","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.3390\/pharmaceutics16111401","article-title":"Abiraterone and galeterone, powerful tools against prostate cancer: present and perspective","volume":"16","author":"Kuzminac","year":"2024","journal-title":"Pharmaceutics"},{"issue":"10","key":"10.1016\/j.steroids.2026.109807_b0115","doi-asserted-by":"crossref","DOI":"10.1002\/cbdv.202200648","article-title":"Design, synthesis and anticancer activity of novel steroidal derivatives with D-ring fused or substituted N-heterocyclic systems","volume":"19","author":"Li","year":"2022","journal-title":"Chem. Biodiversity"},{"issue":"13","key":"10.1016\/j.steroids.2026.109807_b0120","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1021\/jm00013a022","article-title":"Novel steroidal inhibitors of human cytochrome P45017a (17a-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer","volume":"38","author":"Potter","year":"1995","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.steroids.2026.109807_b0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jsbmb.2014.01.013","article-title":"A-Ring modified steroidal azoles retaining similar potent and slowly reversible CYP17A1 inhibition as abiraterone","volume":"143","author":"Garrido","year":"2014","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.steroids.2026.109807_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsbmb.2023.106362","article-title":"Novel D-modified heterocyclic androstane derivatives as potential anticancer agents: Synthesis, characterization, in vitro and in silico studies","volume":"233","author":"\u0160esti\u0107","year":"2023","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.steroids.2026.109807_b0135","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejmech.2017.12.094","article-title":"Synthesis and biological evaluation of new steroidal pyridines as potential anti-prostate cancer agents","volume":"145","author":"Shi","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.steroids.2026.109807_b0140","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ejmech.2019.06.040","article-title":"Synthesis of novel galeterone derivatives and evaluation of their in vitro activity against prostate cancer cell lines","volume":"179","author":"Jorda","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.steroids.2026.109807_b0145","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1021\/jm970337k","article-title":"17-Imidazolyl, pyrazolyl, and isoxazolyl androstene derivatives. Novel steroidal inhibitors of human cytochrome C17,20-lyase (P45017a)","author":"Ling","year":"1997","journal-title":"Journal of Medicinal Chemistry 40(20)"},{"key":"10.1016\/j.steroids.2026.109807_b0150","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ejmech.2016.05.006","article-title":"Synthesis of novel 17-(4'-formyl)pyrazolylandrosta-5,16-dienes and their derivatives as potent 17\u03b1-hydroxylase\/C17,20-lyase inhibitors or antiproliferative agents depending on the substitution pattern of the heteroring","volume":"120","author":"Kov\u00e1cs","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.steroids.2026.109807_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.steroids.2019.03.003","article-title":"Design and synthesis of novel steroidal imidazoles as dual inhibitors of AR\/CYP17 for the treatment of prostate cancer","volume":"150","author":"Hou","year":"2019","journal-title":"Steroids"},{"key":"10.1016\/j.steroids.2026.109807_b0160","doi-asserted-by":"crossref","unstructured":"D.J. McCarty, W. Huang, M.A. Kane, P. Purushottamachar, L.K. Gediya, V.C.O. Njar, Novel galeterone analogs act independently of AR and AR-V7 for the activation of the unfolded protein response and induction of apoptosis in the CWR22Rv1 prostate cancer cell model, Oncotarget 8(51) (2017) 88501-88516. 10.18632\/oncotarget.19762.","DOI":"10.18632\/oncotarget.19762"},{"issue":"11","key":"10.1016\/j.steroids.2026.109807_b0165","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.3390\/cancers11111637","article-title":"Galeterone and the next generation galeterone analogs, VNPP414 and VNPP433-3\u03b2 exert potent therapeutic effects in castration-\/drug-resistant prostate cancer preclinical models in vitro and in vivo","volume":"11","author":"Kwegyir-Afful","year":"2019","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.steroids.2026.109807_b0170","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1021\/jm970568r","article-title":"Novel 17-azolyl steroids, potent inhibitors of human cytochrome 17a-hydroxylase-C17,20-lyase (P45017a): potential agents for the treatment of prostate cancer","volume":"41","author":"Njar","year":"1998","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.steroids.2026.109807_b0175","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1039\/D4MD00297K","article-title":"Synthesis and biological evaluation of novel D-ring fused steroidal N(2)-substituted-1,2,3-triazoles","volume":"16","author":"Tenjovi\u0107","year":"2025","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.steroids.2026.109807_b0180","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.steroids.2014.06.014","article-title":"Novel oxazolinyl derivatives of pregna-5,17(20)-diene as 17a-hydroxylase\/17,20-lyase (CYP17A1) inhibitors","volume":"88","author":"Kuzikov","year":"2014","journal-title":"Steroids"},{"key":"10.1016\/j.steroids.2026.109807_b0185","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.steroids.2016.06.002","article-title":"Oxazolinyl derivatives of [17(20)E]-21-norpregnene differing in the structure of a and B rings. Facile synthesis and inhibition of CYP17A1 catalytic activity","author":"Kostin","year":"2016","journal-title":"Steroids 115"},{"key":"10.1016\/j.steroids.2026.109807_b0190","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.steroids.2017.11.009","article-title":"Comparison of [17(20)E]-21-norpregnene oxazolinyl and benzoxazolyl derivatives as inhibitors of CYP17A1 activity and prostate carcinoma cells growth","volume":"129","author":"Zolottsev","year":"2018","journal-title":"Steroids"},{"issue":"45","key":"10.1016\/j.steroids.2026.109807_b0195","doi-asserted-by":"crossref","DOI":"10.1002\/slct.202203393","article-title":"Design and synthesis of new agents for prostate cancer treatment inspired by steroidal CYP17\u2005A1 inhibitors","volume":"7","author":"Zolottsev","year":"2022","journal-title":"ChemistrySelect"},{"key":"10.1016\/j.steroids.2026.109807_b0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.steroids.2019.108534","article-title":"New steroidal oxazolines, benzoxazoles and benzimidazoles related to abiraterone and galeterone","volume":"153","author":"Latysheva","year":"2020","journal-title":"Steroids"},{"key":"10.1016\/j.steroids.2026.109807_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103142","article-title":"Novel steroidal 1,3,4-thiadiazines: Synthesis and biological evaluation in androgen receptor-positive prostate cancer 22Rv1 cells","volume":"91","author":"Komendantova","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.steroids.2026.109807_b0210","doi-asserted-by":"crossref","DOI":"10.1039\/D6MD00076B","article-title":"A comprehensive study of novel pregnenolone-isoxazole hybrids as selective inducers of mitochondrial apoptosis in breast cancer cells","author":"Malakhova","year":"2026","journal-title":"RSC Med. Chem."},{"issue":"2","key":"10.1016\/j.steroids.2026.109807_b0215","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1134\/S107042801902012X","article-title":"Chemoselective synthesis of the 14\u03b2-(isoxazol-3-yl)methyl estrane steroids and their transformation with the cleavage of heterocyclic nucleus","volume":"55","author":"Baranovsky","year":"2019","journal-title":"Russ. J. Org. Chem."},{"issue":"11","key":"10.1016\/j.steroids.2026.109807_b0220","doi-asserted-by":"crossref","first-page":"8213","DOI":"10.1039\/D4RA08339C","article-title":"Advances in isoxazole chemistry and their role in drug discovery","volume":"15","author":"Martis","year":"2025","journal-title":"RSC Adv."},{"key":"10.1016\/j.steroids.2026.109807_b0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116328","article-title":"Discovery and characterization of potent spiro-isoxazole-based cereblon ligands with a novel binding mode","volume":"270","author":"Shevalev","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.steroids.2026.109807_b0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116521","article-title":"Novel O-acylated (E)-3-aryl-6,7-dihydrobenzisoxazol-4(5H)-one oximes targeting HSP90-HER2 axis in breast cancer cells","volume":"53","author":"Piven","year":"2022","journal-title":"Bioorg. Med. Chem."},{"issue":"1","key":"10.1016\/j.steroids.2026.109807_b0235","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1054\/bjoc.2000.1136","article-title":"Anti-tumour effects and pharmacokinetic profile of 17-(5'-isoxazolyl)androsta-4,16-dien-3-one (L-39) in mice: an inhibitor of androgen synthesis","volume":"83","author":"Nnane","year":"2000","journal-title":"Br. J. Cancer"},{"issue":"11","key":"10.1016\/j.steroids.2026.109807_b0240","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.steroids.2012.05.003","article-title":"Synthesis, characterization and biological evaluation of some novel 17-isoxazoles in the estrone series","volume":"77","author":"Kov\u00e1cs","year":"2012","journal-title":"Steroids"},{"issue":"3","key":"10.1016\/j.steroids.2026.109807_b0245","doi-asserted-by":"crossref","DOI":"10.1002\/hc.21372","article-title":"Synthesis and antiproliferative activity of 3\u03b1-hydroxyl-3\u03b2-methoxymethyl-5\u03b1-pregnan-20-one with a C-21 hydrophilic substituent","volume":"28","author":"Tsai","year":"2017","journal-title":"Heteroat. Chem"},{"key":"10.1016\/j.steroids.2026.109807_b0250","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.steroids.2018.08.004","article-title":"New azole derivatives of [17(20)E]-21-norpregnene: synthesis and inhibition of prostate carcinoma cell growth","volume":"147","author":"Dalidovich","year":"2019","journal-title":"Steroids"},{"key":"10.1016\/j.steroids.2026.109807_b0255","doi-asserted-by":"crossref","first-page":"13534","DOI":"10.3390\/ijms232113534","article-title":"Synthesis and biological evaluation of new isoxazolyl steroids as anti-prostate cancer agents","volume":"23","author":"Rudovich","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"17","key":"10.1016\/j.steroids.2026.109807_b0260","doi-asserted-by":"crossref","first-page":"4026","DOI":"10.3390\/molecules29174026","article-title":"Effects of isoxazolyl steroids on key genes of Sonic Hedgehog cascade expression in tumor cells","volume":"29","author":"Aleksandrova","year":"2024","journal-title":"Molecules"},{"key":"10.1016\/j.steroids.2026.109807_b0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.steroids.2025.109599","article-title":"Isoxazolyl steroid blocks the Shh signaling pathway and the expression of MMP-2 and MMP-9 in cervical carcinoma cell lines","volume":"217","author":"Timoshenko","year":"2025","journal-title":"Steroids"},{"key":"10.1016\/j.steroids.2026.109807_b0270","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.3762\/bjoc.10.161","article-title":"C\u2013H-Functionalization logic guides the synthesis of a carbacyclopamine analog","volume":"10","author":"Rabe","year":"2014","journal-title":"Beilstein J. Org. Chem."},{"issue":"2","key":"10.1016\/j.steroids.2026.109807_b0275","first-page":"105","article-title":"Enhanced control of proliferation in telomerized cells","volume":"38","author":"Egorov","year":"2007","journal-title":"Ontogenez"},{"issue":"18","key":"10.1016\/j.steroids.2026.109807_b0280","volume":"23","author":"Zapevalova","year":"2022","journal-title":"Synthesis, Molecular Docking, in Vitro and in Vivo Studies of Novel Dimorpholinoquinazoline-Based Potential Inhibitors of PI3K\/Akt\/mTOR Pathway, International Journal of Molecular Sciences"},{"key":"10.1016\/j.steroids.2026.109807_b0285","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","article-title":"A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding","volume":"72","author":"Bradford","year":"1976","journal-title":"Anal. Biochem."},{"issue":"9","key":"10.1016\/j.steroids.2026.109807_b0290","doi-asserted-by":"crossref","first-page":"429","DOI":"10.4103\/1947-2714.100998","article-title":"Western blot: technique, theory, and trouble shooting","volume":"4","author":"Mahmood","year":"2012","journal-title":"N. Am. J. Med. Sci."},{"issue":"2","key":"10.1016\/j.steroids.2026.109807_b0295","doi-asserted-by":"crossref","first-page":"121","DOI":"10.4161\/spmg.1.2.16606","article-title":"Enhanced chemiluminescence (ECL) for routine immunoblotting: an inexpensive alternative to commercially available kits","volume":"1","author":"Mruk","year":"2011","journal-title":"Spermatogenesis"},{"issue":"7","key":"10.1016\/j.steroids.2026.109807_b0300","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1134\/S0006297908070092","article-title":"Engineering, expression, and purification of \u201csoluble\u201d human cytochrome P45017a and its functional characterization","volume":"73","author":"Pechurskaya","year":"2008","journal-title":"Biochemistry. Biokhimiia"},{"issue":"11","key":"10.1016\/j.steroids.2026.109807_b0305","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11112873","article-title":"Molecular cloning, heterologous expression, purification, and evaluation of protein-ligand interactions of CYP51 of Candida krusei azole-resistant fungal strain","volume":"11","author":"Tsybruk","year":"2023","journal-title":"Biomedicines"},{"issue":"9","key":"10.1016\/j.steroids.2026.109807_b0310","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1071\/CH12062","article-title":"Regioselective addition of 1,3-dicarbonyl dianions to carbonyl compounds: one pot lactonization and ketalization of \u03b4-hydroxy-\u03b2-keto esters to protected pyrone derivatives","volume":"65","author":"Ghorai","year":"2012","journal-title":"Aust. J. Chem."},{"issue":"2","key":"10.1016\/j.steroids.2026.109807_b0315","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/cjoc.201900369","article-title":"Isoxazolone reactivity explained by computed electronic structure analysis","volume":"38","author":"Bella","year":"2020","journal-title":"Chin. J. Chem ."},{"issue":"7","key":"10.1016\/j.steroids.2026.109807_b0320","first-page":"819","article-title":"Experimental and theoretical study on structure-tautomerism among edaravone, isoxazolone, and their heterocycles derivatives as antioxidants","volume":"28","author":"Queiroz","year":"2020","journal-title":"Saudi Pharmaceutical Journal : SPJ : the Official Publication of the Saudi Pharmaceutical Society"},{"issue":"3","key":"10.1016\/j.steroids.2026.109807_b0325","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41416-018-0158-y","article-title":"Abiraterone shows alternate activity in models of endocrine resistant and sensitive disease","volume":"119","author":"Simigdala","year":"2018","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.steroids.2026.109807_b0330","first-page":"107","volume":"93","author":"Kova\u010devi\u0107","year":"2016","journal-title":"Pharmaceutical Sciences"},{"issue":"13","key":"10.1016\/j.steroids.2026.109807_b0335","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.2174\/1871520618666180426100942","article-title":"Synthesis, 17\u03b1-hydroxylase-C17,20-lyase Inhibitory and 5AR reductase activity of novel pregnenolone derivatives","volume":"18","author":"Banday","year":"2018","journal-title":"Anticancer Agents Med Chem."},{"key":"10.1016\/j.steroids.2026.109807_b0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsbmb.2025.106745","article-title":"Secosteroid - 1,3,4-oxadiazole hybrids: Synthesis and evaluation of their activity against hormone-dependent breast cancer cells","volume":"251","author":"Ilovaisky","year":"2025","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.steroids.2026.109807_b0345","doi-asserted-by":"crossref","unstructured":"D.G. Nair, R. Weiskirchen, Advanced In Vitro Models for Preclinical Drug Safety: Recent Progress and Prospects, Current issues in molecular biology 47(1) (2024). 10.3390\/cimb47010007.","DOI":"10.3390\/cimb47010007"},{"issue":"2","key":"10.1016\/j.steroids.2026.109807_b0350","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1039\/D0MD00317D","article-title":"Normal breast epithelial MCF-10A cells to evaluate the safety of carbon dots","volume":"12","author":"Vale","year":"2021","journal-title":"RSC Med. Chem."},{"issue":"23","key":"10.1016\/j.steroids.2026.109807_b0355","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25235514","article-title":"Essential Oil from Melaleuca leucadendra: Antimicrobial, Antikinetoplastid, Antiproliferative and Cytotoxic Assessment","volume":"25","author":"Monzote","year":"2020","journal-title":"Molecules"},{"issue":"2","key":"10.1016\/j.steroids.2026.109807_b0360","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1128\/MCB.05958-11","article-title":"Integration of regulatory networks by NKX3-1 promotes androgen-dependent prostate cancer survival","volume":"32","author":"Tan","year":"2012","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.steroids.2026.109807_b0365","doi-asserted-by":"crossref","unstructured":"B. Gurel, T.Z. Ali, E.A. Montgomery, S. Begum, J. Hicks, M. Goggins, C.G. Eberhart, D.P. Clark, C.J. Bieberich, J.I. Epstein, A.M. De Marzo, NKX3.1 as a marker of prostatic origin in metastatic tumors, The American journal of surgical pathology 34(8) (2010) 1097-105. 10.1097\/PAS.0b013e3181e6cbf3.","DOI":"10.1097\/PAS.0b013e3181e6cbf3"},{"key":"10.1016\/j.steroids.2026.109807_b0370","doi-asserted-by":"crossref","unstructured":"B.Y. Shorning, M.S. Dass, M.J. Smalley, H.B. Pearson, The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling, International journal of molecular sciences 21(12) (2020). 10.3390\/ijms21124507.","DOI":"10.3390\/ijms21124507"},{"key":"10.1016\/j.steroids.2026.109807_b0375","doi-asserted-by":"crossref","unstructured":"E. Tortorella, S. Giantulli, A. Sciarra, I. Silvestri, AR and PI3K\/AKT in Prostate Cancer: A Tale of Two Interconnected Pathways, International journal of molecular sciences 24(3) (2023). 10.3390\/ijms24032046.","DOI":"10.3390\/ijms24032046"},{"key":"10.1016\/j.steroids.2026.109807_b0380","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1186\/s12885-016-2629-y","article-title":"S6Ks isoforms contribute to viability, migration, docetaxel resistance and tumor formation of prostate cancer cells","volume":"16","author":"Amaral","year":"2016","journal-title":"BMC Cancer"},{"issue":"7","key":"10.1016\/j.steroids.2026.109807_b0385","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/s41419-022-05081-4","article-title":"Beyond controlling cell size: functional analyses of S6K in tumorigenesis","volume":"13","author":"Wu","year":"2022","journal-title":"Cell Death Dis."},{"issue":"5","key":"10.1016\/j.steroids.2026.109807_b0390","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/bcp.12844","article-title":"Therapeutic potential of mTOR inhibitors for targeting cancer stem cells","volume":"82","author":"Francipane","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.steroids.2026.109807_b0395","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/169170","article-title":"MAP Kinases and Prostate Cancer","volume":"2012","author":"Rodr\u00edguez-Berriguete","year":"2012","journal-title":"J. Signal Transduction"},{"issue":"3","key":"10.1016\/j.steroids.2026.109807_b0400","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/ijc.22715","article-title":"Ras-MEK-ERK signaling cascade regulates androgen receptor element-inducible gene transcription and DNA synthesis in prostate cancer cells","volume":"121","author":"Carey","year":"2007","journal-title":"Int. J. Cancer"},{"issue":"3","key":"10.1016\/j.steroids.2026.109807_b0405","first-page":"187","article-title":"Androgen receptor-mediated non-genomic regulation of prostate cancer cell proliferation","volume":"2","author":"Liao","year":"2013","journal-title":"Translational Andrology and Urology"}],"container-title":["Steroids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039128X26000693?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039128X26000693?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T14:26:07Z","timestamp":1786026367000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039128X26000693"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":81,"alternative-id":["S0039128X26000693"],"URL":"https:\/\/doi.org\/10.1016\/j.steroids.2026.109807","relation":{},"ISSN":["0039-128X"],"issn-type":[{"value":"0039-128X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis and cytotoxicity evaluation of steroidal 17\u03b2-hydroxy-17\u03b1-methylisoxazoles","name":"articletitle","label":"Article Title"},{"value":"Steroids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.steroids.2026.109807","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109807"}}